Boloori Alireza, Saghafian Soroush, Chakkera Harini A, Cook Curtiss B
Department of Industrial Engineering, School of Computing, Informatics and Decision Systems Engineering, Arizona State University, Tempe, Arizona, United States of America.
Harvard Kennedy School, Harvard University, Cambridge, Massachusetts, United States of America.
PLoS One. 2015 Nov 9;10(11):e0142363. doi: 10.1371/journal.pone.0142363. eCollection 2015.
Hyperglycemia following solid organ transplant is common among patients without pre-existing diabetes mellitus (DM). Post-transplant hyperglycemia can occur once or multiple times, which if continued, causes new-onset diabetes after transplantation (NODAT).
To study if the first and recurrent incidence of hyperglycemia are affected differently by immunosuppressive regimens, demographic and medical-related risk factors, and inpatient hyperglycemic conditions (i.e., an emphasis on the time course of post-transplant complications).
We conducted a retrospective analysis of 407 patients who underwent kidney transplantation at Mayo Clinic Arizona. Among these, there were 292 patients with no signs of DM prior to transplant. For this category of patients, we evaluated the impact of (1) immunosuppressive drugs (e.g., tacrolimus, sirolimus, and steroid), (2) demographic and medical-related risk factors, and (3) inpatient hyperglycemic conditions on the first and recurrent incidence of hyperglycemia in one year post-transplant. We employed two versions of Cox regression analyses: (1) a time-dependent model to analyze the recurrent cases of hyperglycemia and (2) a time-independent model to analyze the first incidence of hyperglycemia.
Age (P = 0.018), HDL cholesterol (P = 0.010), and the average trough level of tacrolimus (P<0.0001) are significant risk factors associated with the first incidence of hyperglycemia, while age (P<0.0001), non-White race (P = 0.002), BMI (P = 0.002), HDL cholesterol (P = 0.003), uric acid (P = 0.012), and using steroid (P = 0.007) are the significant risk factors for the recurrent cases of hyperglycemia.
This study draws attention to the importance of analyzing the risk factors associated with a disease (specially a chronic one) with respect to both its first and recurrent incidence, as well as carefully differentiating these two perspectives: a fact that is currently overlooked in the literature.
实体器官移植后高血糖在无糖尿病(DM)病史的患者中很常见。移植后高血糖可发生一次或多次,如果持续存在,会导致移植后新发糖尿病(NODAT)。
研究免疫抑制方案、人口统计学和医学相关危险因素以及住院高血糖状况(即强调移植后并发症的时间进程)对高血糖首次发作和复发发生率的影响是否不同。
我们对在亚利桑那州梅奥诊所接受肾移植的407例患者进行了回顾性分析。其中,292例患者在移植前无DM迹象。对于这类患者,我们评估了(1)免疫抑制药物(如他克莫司、西罗莫司和类固醇)、(2)人口统计学和医学相关危险因素以及(3)住院高血糖状况对移植后一年内高血糖首次发作和复发发生率的影响。我们采用了两种版本的Cox回归分析:(1)一个时间依赖性模型来分析高血糖复发病例,(2)一个时间独立性模型来分析高血糖首次发作情况。
年龄(P = 0.018)、高密度脂蛋白胆固醇(HDL胆固醇,P = 0.010)和他克莫司的平均谷浓度(P<0.0001)是与高血糖首次发作相关的显著危险因素,而年龄(P<0.0001)、非白人种族(P = 0.002)、体重指数(BMI,P = 0.002)、HDL胆固醇(P = 0.003)、尿酸(P = 0.012)和使用类固醇(P = 0.007)是高血糖复发病例的显著危险因素。
本研究提请注意分析与一种疾病(特别是慢性疾病)首次发作和复发发生率相关的危险因素的重要性,以及仔细区分这两个观点:这一事实目前在文献中被忽视。